Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice

Sölétormos, György; Semjonow, Axel; Sibley, Paul; Lamerz, R.; Petersen, Per Hyltoft; Albrecht, Walter; Bialk, Peter; Gion, Massimo; Junker, Frank; Schmid, Hans‐Peter; Poppel, Hendrik Van

doi:10.1373/clinchem.2004.046086

Cited by 120 publications

(88 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In screening studies [4,6] or studies using stored sera [3,14] in which PSA samples are taken annually or biannually, the PSAV calculated by AE will be similar to that of LR. However, regular time intervals between PSA tests may not occur in clinical practice, particularly given recent recommendations to repeat an abnormal PSA before proceeding with invasive investigations [16,17]. In this population-based study, only 11.6% of men had at least 9 mo between each PSA, limiting the widespread usefulness of PSAV if strict time constraints are applied.…”

Section: Discussionmentioning

confidence: 96%

“…Short-term variations in PSA are common [3,16,17] and, although factors such as infection and prostatic manipulation can artificially increase the PSA value [18], there is also an inherent biologic variability of PSA. A recent systematic review including 12 studies that examined PSA variability estimated the mean variation between tests to be 20% ($33% at 95% confidence interval) [17]. A true PSA of 4.5 ng/ml may therefore produce measured PSA results ranging from 3.0-6.0 ng/ml.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Methods of Calculating Prostate-Specific Antigen Velocity

et al. 2007

View full text Add to dashboard Cite

e u r o p e a n u r o l o g y 5 2 ( 2 0 0 7 ) 1 0 4 4 -1 0 5 1 a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j o u r n a l h o m e p a g e : w w w . e u r o p e a n u r o l o g y . c o m Article info AbstractObjectives: Numerous methods of calculating PSA velocity (PSAV) are used and have the potential to produce differing PSAV results from the same PSA data. We calculated PSAV using three common methods and compared differences between the methods and their predictive value for prostate cancer diagnosis. Methods: From a population-based database of PSA results, men with initial PSA < 10.0 ng/ml and a subsequent diagnosis of prostate cancer or benign histology were identified. Those with !3 PSA tests before diagnosis carried out over a minimum of 18 mo were included. PSAV was calculated by using three methods:1. Arithmetic equation of change in PSA over time (AE) 2. Linear regression (LR) 3. Rate of PSA change using first and last values only (FL)The differences between the methods and test characteristics of each method were compared. Results: Of the 2204 men included, 716 (32.5%) were diagnosed with prostate cancer and 1488 (67.5%) benign histology. PSAV differed markedly in each method of calculation. The LR and FL methods had similar predictive values, which were higher than the AE method. There was strong agreement for cancer diagnosis between LR and FL (kappa = 0.85), with weaker agreement between LR/AE and FL/AE (kappa = 0.69 and 0.66, respectively). Conclusions: Methods used to calculate PSAV using the same PSA data can produce markedly different results. Linear regression should be the method of choice for calculating PSAV. Using first and last PSA values only may be adequate for everyday clinical use, as long as measurements are separated by a sufficiently long time period.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Methods of Calculating Prostate-Specific Antigen Velocity

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Finally, studies have shown that in patients with prostatic disease, there can be a 20-60% variability between PSA measurements. 2,30 Due to these potential sources of error, it is important to adhere to the National Academy of Clinical Biochemistry guidelines for the measurement of tumor markers. 2 These guidelines recommend that laboratories be aware of the possibility of analytical interferences, and that assay interferences should be considered whenever a tumor marker result does not agree with a patient's clinical picture.…”

Section: Discussionmentioning

confidence: 99%

Spurious elevation of serum PSA after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies

Anderson

Pyle

Woodworth

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

“…by Söletormos et al [10] on behalf of the European Group on Tumor Markers. The CV I values from 13 studies varied between 2.1% and 22.9%.…”

Section: New Concept For Defining Permissible Performance Criteriamentioning

confidence: 99%

Optimizing the use of the “state-of-the-art” performance criteria

Haeckel

Wosniok

Streichert

2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Abstract:The organizers of the first EFLM Strategic Conference "Defining analytical performance goals" identified three models for defining analytical performance goals in laboratory medicine. Whereas the highest level of model 1 (outcome studies) is difficult to implement, the other levels are more or less based on subjective opinions of experts, with models 2 (based on biological variation) and 3 (defined by the state-of-the-art) being more objective. A working group of the German Society of Clinical Chemistry and Laboratory Medicine (DGKL) proposes a combination of models 2 and 3 to overcome some disadvantages inherent to both models. In the new model, the permissible imprecision is not defined as a constant proportion of biological variation but by a non-linear relationship between permissible analytical and biological variation. Furthermore, the permissible imprecision is referred to the target quantity value. The biological variation is derived from the reference interval, if appropriate, after logarithmic transformation of the reference limits.

show abstract

Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice

Cited by 120 publications

References 69 publications

Methods of Calculating Prostate-Specific Antigen Velocity

Methods of Calculating Prostate-Specific Antigen Velocity

Spurious elevation of serum PSA after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies

Optimizing the use of the “state-of-the-art” performance criteria

Contact Info

Product

Resources

About